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Background:   Hypertrophic cardiomyopathy (HCM) has been prominently associated with grim prognosis and adverse disease 
complications, most visibly arrhythmic sudden death (SD), once associated with an annual mortality of up to 6%. Whether recent advances 
in management strategy, including implantable cardioverter-defibrillators (ICDs), or other therapeutic measures do, in fact, significantly 
improve survival and alter clinical course for adult HCM patients is an important consideration.
methods:  We addressed long-term outcome in a cohort of 1000 consecutive adult HCM patients presenting between 30 and 59 years of 
age, 1992-2011.
results:  Over 7.2 ± 5.2 years of follow-up, 918 patients (92%) survived to 53 ± 9.2 years of age (range 32-80) with 91% experiencing 
no or only mild symptoms at last evaluation. HCM-related death occurred in 40 patients (4%; 0.53%/year) at 50 ± 10 years, including: 
progressive heart failure (n = 17), arrhythmic SD (n = 17), embolic stroke (n = 2). In contrast, 56 other high-risk patients survived life-
threatening events (5.6%), most commonly with ICD interventions for ventricular tachyarrhythmias (n = 33), 0.79%/year. Notably, of the 17 
sudden deaths, 6 occurred in patients who declined a formal recommendation for prophylactic ICD therapy based on standard risk factor 
assessment, and 11 were either initially evaluated in the 1990s prior to general employment of ICDs for HCM, or had no risk factors to 
justify an ICD decision. Survival at 5 and 10 years (considering only HCM death) was 98% and 94%, not different from that expected for 
all-cause mortality in the U.S. population (p = 0.25).
conclusion:  In a large longitudinally assessed adult HCM cohort, treatment interventions, including ICDs for SD prevention, have altered 
clinical course resulting in a low disease-related mortality rate, with the opportunity for extended longevity. Contemporary management 
strategies have substantially reduced SD as a cause of mortality in HCM, with heart failure-related deaths now predominant.
